Spots Global Cancer Trial Database for Alimta, Carboplatin and Radiation Therapy for Non Small Cell Lung Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Alimta, Carboplatin and Radiation Therapy for Non Small Cell Lung Cancer
Official Title: A Phase I Study of Premetrexed (Alimta) and Carboplatin and Radiation Therapy in Patients With Inoperable Non Small Cell Lung Cancer.
Study ID: NCT00330044
Conditions
Study Description
Brief Summary: To determine the safety of Alimta when used with chemoradiation in inoperable non small cell lung cancer
Detailed Description: To determine the maximal tolerated dose (MTD) and toxicities of Pemetrexed (Alimta) when administered concurrently with carboplatin and thoracic radiation therapy. To determine, qualitatively, the occurrence of local tumor responses identified with this regimen.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
Contact Details
Name: Maria Werner-Wasik, MD
Affiliation: Thomas Jefferson University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
